Industry Group Exploring Number of Batches for Early Stage Validation
This article was originally published in The Gold Sheet
An upcoming ISPE discussion paper aims to help manufacturers decide on the correct number of batches to run to demonstrate that a process is in a state of control in early stage validation studies.
You may also be interested in...
Pharmaceutical lndustry Proposes Ideas for Number of Batches, Monitoring Production
The pharmaceutical industry is advancing ideas for estimating the number of batches to run during process validation as well as how to establish robust monitoring and testing programs for products on the market. Industry has been hammering out these details in the absence of many specifics in the FDA’s 2011 process validation guidance on these areas.
FDA Guidance Exempts Legacy Products from Early Stage Process Validation; Endorses Use of PAT
FDA’s final process validation guidance clarifies that legacy products, or products that are currently on the market, will be exempt from early stage process validation. The guidance also endorses the use of process analytical technology for monitoring product quality.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”